Exploring the potential of T-cell therapy for acute lymphoblastic leukemia

At the 20th Congress of the European Hematology Association (EHA), Dieter Hoelzer, MD, PhD, of Goethe University Hospital, Frankfurt, Germany, discusses T-cell engagement strategies for the treatment of patients with acute lymphoblastic leukemia (ALL), including bispecific antibody constructs (BiTEs); chimeric antigen-receptor (CAR) T-cells; the role of minimal residual disease (MRD) in these approaches; and the impact on patient selection for transplant.